Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Increased nuchal translucency with normal karyotype].

M-V Senat1, R Frydman

  • 1Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Antoine-Béclère, APHP, Clamart cedex, France. marie-victoire.senat@abc.aphp.fr <marie-victoire.senat@abc.aphp.fr>

Gynecologie, Obstetrique & Fertilite
|May 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Intrahepatic cholestasis of pregnancy: French College of Obstetricians and Gynecologists guidelines for clinical practice].

Gynecologie, obstetrique, fertilite & senologie·2023
Same author

[The cesarean procedure: Guidelines for clinical practice from the French College of Obstetricians and Gynecologists].

Gynecologie, obstetrique, fertilite & senologie·2022
Same author

[Expert consensus from the College of French Gynecologists and Obstetricians: Management of nausea and vomiting of pregnancy and hyperemesis gravidarum].

Gynecologie, obstetrique, fertilite & senologie·2022
Same author

[Ante- and postnatal growth charts in France - guidelines for clinical practice from the Collège national des gynécologues et obstétriciens français (CNGOF) and from the Société française de néonatologie (SFN)].

Gynecologie, obstetrique, fertilite & senologie·2022
Same author

[CNGOF clinical practice guidelines: Evaluation one year after revision of the methodology].

Gynecologie, obstetrique, fertilite & senologie·2021
Same author

[Reprint of: Severe pre-eclampsia: guidelines for clinical practice from the French Society of anesthesiology and intensive care (SFAR) and the French College of gynaecologists and obstetricians (CNGOF)].

Gynecologie, obstetrique, fertilite & senologie·2021

Nuchal translucency (NT) screening in early pregnancy identifies risks for aneuploidies and fetal defects. However, normal NT measurements in live-born infants correlate with typical development at age two, regardless of initial screening results.

Area of Science:

  • Prenatal Diagnosis
  • Fetal Medicine
  • Genetics

Background:

  • Nuchal translucency (NT) measurement is a key first-trimester screening marker for fetal aneuploidies, particularly trisomy 21.
  • Increased NT thickness, even without aneuploidy, is associated with fetal heart malformations, other defects, and genetic syndromes.

Purpose of the Study:

  • To evaluate the long-term developmental outcomes in children born after first-trimester NT screening.
  • To determine if increased NT thickness, in the absence of aneuploidy or structural anomalies, impacts neurodevelopment at two years of age.

Main Methods:

  • Retrospective analysis of first-trimester NT measurements and subsequent prenatal diagnoses.
  • Follow-up assessment of neurodevelopmental outcomes at two years using clinical examination and Ages and Stages Questionnaires (ASQ) in live-born infants.

Related Experiment Videos

Main Results:

  • Fetuses with NT above the 99th centile and normal karyotype face an exponentially increasing risk of adverse prenatal outcomes.
  • No significant association was found between first-trimester NT thickness and neurodevelopmental outcomes at two years in children born alive with normal 22-week ultrasounds.

Conclusions:

  • While elevated NT is a marker for significant prenatal risks, normal karyotype and absence of structural anomalies suggest a positive prognosis.
  • Resolution of nuchal thickening in fetuses with normal karyotypes and no missed structural malformations indicates unimpaired neurodevelopmental prognosis at age two.